Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
With the aim of finding a prospective therapeutic compound with a promising potential for the treatment of urolithiasis, we evaluated the effectiveness of a new potent inhibitor of urease, N-(pivaloyl)glycinohydroxamic acid. The present study revealed that N-(pivaloyl)glycinohydroxamic acid effectively inhibited the alkalinization of urine and the stone formation in vitro and in vivo, due to its strong inhibitory potency against the ureolytic activity of intact Proteus mirabilis. The possibility of the clinical application of this compound in the prevention of struvite stone formation caused by infection of urea-splitting bacteria awaits evaluation of the safety of this compound.
D000818:Animals; D004195:Disease Models, Animal; D006863:Hydrogen-Ion Concentration; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011512:Proteus Infections / Q000150:complications; D011513:Proteus mirabilis / Q000187:drug effects; D051381:Rats; D014510:Urease / Q000037:antagonists & inhibitors*; D014545:Urinary Calculi / Q000382:microbiology / Q000517:prevention & control*; D014556:Urine / Q000032:analysis
D006877:Hydroxamic Acids; C032346:N-(pivaloyl)glycinohydroxamic acid; D014510:Urease